KRAS and lung adenocarcinoma: In sum, EGFR palmitoylation appears to be required for PI3K–AKT–Myc signalling in Kras-mutant lung adenocarcinoma, revealing DHHC20 inhibition as a therapeutic vulnerability in the PI3K–AKT pathway.